Clinical Study Report

Trial,study,time,safety,review,outcomes,risk,submission,placebo,adverse events,event,clinical study,product,clinical trial,clinical study reports,study protocol,U.S.

Primary outcome measures,regulatory agencies,statistical analyses,study sponsor,biological products,U.S. Food and Drug Administration,Institutional Review Board.

Primary outcomes,Secondary outcome measures,illness,adults,study design,medicinal product,influenza,symptom,duration of symptoms,healthy adults,Food and Drug Administration,Clinical Study Reports,study arm,investigational drug product.

Product development,asymptomatic influenza,prophylaxis of influenza,complications of influenza,treatment of influenza,influenza in contacts,U.S. FDA,systematic reviews,risk ratio,risk differences,clinical trial registration information,placebo capsules,randomised placebo,standard submission deadline,delayed submission,influenza-like illness,symptomatic influenza-like illness,safety monitoring board,alleviation of symptoms,symptoms in adults,calendar days,National Library of Medicine,hazard ratios,legal consequences,medical care,United States,Doshi P,electronic databases,harms of NIs,Jefferson T,pediatric postmarket surveillance,Chris Del Mar,drug clinical,unpublished reports,applicable device,device clinical,Age-related Eye Disease Study,Study Research Group,Age-Related Eye Disease Study Research Group,Age-Related Eye Disease Study 2 Research Group,onset studies,Study Records,Age-Related Eye Disease Study 2 (AREDS2),applications with studies,Device Product,U.S. FDA-regulated Device Product,U.S. FDA-regulated Drug Product,Combined Review,QC review,risk of complications,risk of headaches,prophylaxis trials,time to recovery,shorter time,time of application,renal events,safety monitoring plan.